Anzeige
Mehr »
Login
Sonntag, 26.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JL0A | ISIN: SE0011167170 | Ticker-Symbol: 9HX
Frankfurt
24.01.25
08:07 Uhr
0,155 Euro
-0,007
-4,32 %
Branche
Hardware
Aktienmarkt
Sonstige
1-Jahres-Chart
FREEMELT HOLDING AB Chart 1 Jahr
5-Tage-Chart
FREEMELT HOLDING AB 5-Tage-Chart
GlobeNewswire (Europe)
202 Leser
Artikel bewerten:
(1)

Freemelt Holding AB: Bulletin from the extraordinary general meeting in Freemelt Holding AB (publ)

Finanznachrichten News

At the extraordinary general meeting (the "EGM") in Freemelt Holding AB (publ) (the "Company") on Friday 24 January 2025, the following resolutions were adopted:

Resolution on amendment to the articles of association

The EGM resolved, in accordance with the board of directors' proposal, on an amendment to the articles of association with respect to the limits on the Company's share capital and number of shares (§§ 4 and 5) as set out below.

  • The share capital must be a minimum of SEK 6,000,000 and a maximum of SEK 24,000,000. The number of shares shall be a minimum of 120,000,000 and a maximum of 480,000,000. All shares are of the same class.
  • The share capital must be a minimum of SEK 24,000,000 and a maximum of SEK 48,000,000. The number of shares shall be a minimum of 480,000,000 and a maximum of 960,000,000. All shares are of the same class.
  • The share capital must be a minimum of SEK 24,000,000 and a maximum of SEK 96,000,000. The number of shares shall be a minimum of 480,000,000 and a maximum of 1,920,000,000. All shares are of the same class.
  • The share capital must be a minimum of SEK 96,000,000 and a maximum of SEK 384,000,000. The number of shares shall be a minimum of 1,920,000,000 and a maximum of 7,680,000,000. All shares are of the same class.

The EGM further resolved to authorise the board of directors to submit for registration with the Swedish Companies Registration Office, the articles of association which limits for the minimum and maximum number of shares and share capital in the Company are compatible with the total number of shares and share capital in the Company after the board of directors has resolved on a new issue of shares and warrants with preferential rights for the Company's shareholders on the basis of the issue authorisation as set out below (including any related issues of shares and warrants with deviation from the shareholders' preferential rights, which may be carried out in order to fulfill the Company's commitment to pay guarantee commission in the form of shares and warrants in accordance with the aforementioned rights issue).

The EGM further resolved, in accordance with the board of directors' proposal, that the board of directors shall have its seat in the municipality of Gothenburg.

Resolution on issue authorisation

The EGM resolved, in accordance with the board of directors' proposal, to authorise the board of directors to, on one or more occasions, during the period until the next annual general meeting, resolve on issues of new shares and/or warrants, with or without preferential rights for the Company's existing shareholders. The Company's share capital and number of shares may, by virtue of the authorisation, be increased with an amount and number that falls within the limits of the, at any time registered, or by the general meeting adopted, articles of association. New issues may be made against cash payment, in kind and/or through set-off, or otherwise be subject to conditions.

As previously communicated, the board of directors intends to resolve on a rights issue of units of approximately SEK 100 million on or around 27 January 2025.

Contacts

For more information, please contact:
Daniel Gidlund, CEO
daniel.gidlund@freemelt.com
070-246 45 01

Certified Advisor
Eminova Fondkomission AB
adviser@eminova.se

About Us

Founded in 2017 by a team of experienced engineers, Freemelt develops advanced 3D printers for metal components and is based in Gothenburg, Sweden. Freemelt primarily serves companies in the defense, energy, and medical technology sectors in Europe and the U.S., helping them innovate and improve production efficiency. Freemelt's modular printers, designed for industrial applications, support complex geometries and high-performance materials, such as tungsten for defense and energy applications and titanium for medical implants. Backed by strategic investors, Freemelt is well-positioned for continued growth as it advances into the next phase of commercialization. Read more at www.freemelt.com

© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.